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Abstract
Purpose—To examine changes in muscle strength and self-reported physical functioning in men 
receiving androgen deprivation therapy (ADT) for prostate cancer compared to matched controls.
Methods—Prostate cancer patients scheduled to begin ADT (n=62) were assessed within 20 days 
of starting ADT and 6 and 12 months later. Age and geographically-matched prostate cancer 
controls treated with prostatectomy only (n=86) were assessed at similar time intervals. Grip 
strength measured upper body strength, the Chair Rise Test measured lower body strength, and the 
SF-12 Physical Functioning scale measured self-reported physical functioning.
Results—As expected, self-reported physical functioning and upper body muscle strength 
declined in ADT recipients but remained stable in prostate cancer controls. Contrary to 
expectations, lower body muscle strength remained stable in ADT recipients but improved in 
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prostate cancer controls. Higher Gleason scores, more medical comorbidities, and less exercise at 
baseline predicted greater declines in physical functioning in ADT recipients.
Conclusions—ADT is associated with declines in self-reported physical functioning and upper-
body muscle strength as well as worse lower body muscle strength relative to prostate cancer 
controls. These findings should be included in patient education regarding the risks and benefits of 
ADT. Findings also underscore the importance of conducting research on ways to prevent or 
reverse declines in physical functioning in this patient population.
Keywords
prostate cancer; androgen deprivation; physical functioning; Antiandrogens; Physical Activity; 
Muscle Strength; Quality of Life
Introduction
Approximately 45% of men with prostate cancer will be treated with androgen deprivation 
therapy (ADT) as primary treatment or adjuvant to radiation or prostatectomy [9]. ADT 
significantly reduces the risk of mortality in prostate cancer[24], but despite its efficacy 
ADT it is associated with multiple side-effects, including symptoms of sarcopenia (i.e., loss 
of strength or mobility resulting from decreases in lean body mass) [26].
Previous research on decrements in physical functioning secondary to ADT has focused 
mostly on the extent of muscle loss. Studies suggest patients undergoing ADT demonstrate a 
3–4% loss of lean body mass after beginning ADT [12, 23], in contrast, to no change in 
cancer-free older men and a loss of less than 0.5% in prostate cancer patients not treated 
with ADT [29]. Few studies have examined the functional consequences of ADT, such as 
declines in self-reported physical functioning. Some cross-sectional evidence has suggested 
that physical functioning is worse in men treated with ADT compared to controls [7], but 
other studies have failed to find an effect of ADT on physical functioning [27].
In cross-sectional studies, men receiving ADT demonstrated worse upper body strength [2], 
lower body strength [7, 18], self-reported physical functioning [14], and worse physical 
performance [4] than men who did not receive ADT. Others have not observed worse upper 
body strength or lower body strength in ADT recipients [15]. However, only one study has 
examined the impact of ADT on physical functioning longitudinally with a comparison 
group of men with prostate cancer not treated with ADT. In this study, Alibhai and 
colleagues found that ADT recipients reported worse physical functioning and exhibited 
worse upper body strength as well as less exercise tolerance than controls [1]. However, no 
differences were observed for lower body strength and predictors of worse physical 
functioning were not explored. These somewhat inconsistent results and the lack of data on 
predictors of the decline in physical functioning highlight the need for additional research.
In light of sparse and inconsistent evidence linking ADT with reduced lower body strength 
and physical functioning, the present study used a longitudinal design to determine the 
impact of ADT on upper and lower body muscle strength and self-reported physical 
functioning. It was hypothesized that prostate cancer patients treated with ADT would 
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experience declines in physical functioning and muscle strength from the start of ADT to 12 
months later, whereas prostate cancer patients treated with prostatectomy only would not. It 
was also hypothesized that ADT recipients would demonstrate worse physical functioning 
and muscle strength than controls at 6 and 12 months after initiation of ADT. No previous 
studies have examined longitudinal predictors of worsening physical functioning after ADT. 
Thus, additional exploratory analyses sought to identify predictors of individual differences 
of decline in outcomes that worsened significantly in ADT recipients.
Methods
Participants
Participants were recruited as part of a longitudinal study focused on cognitive side effects 
of ADT. The study included two samples: prostate cancer patients starting ADT (ADT 
recipients) and prostate cancer patients treated with prostatectomy only (prostate cancer 
controls). Eligibility criteria required that all participants be ≥ 18 years of age, be able to 
speak and read English, have ≥ eighth grade education, have no history of stroke, and be 
able to provide informed consent. Because the larger study focused on cognitive function, all 
participants were also free of cognitive impairment (Short Portable Mental Status Exam 
score < 3). Additional eligibility criteria for ADT recipients were that they be diagnosed 
with non-metastatic or asymptomatic metastatic prostate cancer, be disease-free or in 
remission for any other cancers, be scheduled to start ADT or have started ADT in past 
month for standard clinical purposes, and have a planned course of ADT treatment of at 
least 6 months. They also had to be free of: treatment for any other cancers in the 12 months 
prior to recruitment; any history of brain cancer; previous treatment with cranial irradiation; 
treatment with ADT in the 12 months prior to recruitment; and treatment with an anti-
androgen agent (e.g., bicalutamide) in the 6 months prior to recruitment.
Additional eligibility criteria for the prostate cancer controls were that they be diagnosed 
with non-metastatic prostate cancer, be free of diagnoses of other cancers except non-
melanoma skin cancer, have undergone prostatectomy, have no history of recurrent disease 
since undergoing prostatectomy, have no history of other forms of prostate cancer treatment 
(e.g., radiotherapy), not be scheduled for additional prostate cancer treatment, and not be 
receiving testosterone supplementation. Prostate cancer controls were matched to an ADT 
recipient on time since diagnosis (within 6 months), age (within 5 years), and education (i.e., 
≤12 years, 13–16 years, or ≥17 years).
Procedure
Data collection began in September, 2008. The grip strength and chair rise tests were added 
in October, 2009. Written informed consent was obtained prior to initiation of study 
procedures. Participants were paid $80 at each evaluation. This study was approved by the 
Institutional Review Board at the University of South Florida.
ADT recipients and prostate cancer controls were recruited from Moffitt Cancer Center. 
ADT recipients were also recruited from the James A. Haley Veterans’ Hospital in Tampa, 
Florida. Baseline assessments were completed before or within one month of starting ADT 
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and 6 and 12 months later. Individuals were contacted by telephone and those eligible and 
interested were scheduled for an appointment at which written informed consent was 
obtained and the baseline assessment conducted. Follow-up assessments were conducted 6 
and 12 months after baseline.
Measures
Demographic and clinical factors were assessed at baseline. Age, education, race, ethnicity, 
and smoking history were assessed via self-report. Time since diagnosis, body mass index, 
Gleason score were assessed via medical chart review. Medical comorbidities were assessed 
using a self-report version of the Charlson Comorbidity Index (CCI) [17].
Self-reported physical functioning was examined at each assessment using the Physical 
Functioning subscale of the Medical Outcomes Study SF-12 scale (SF-12) [30]. Items in this 
subscale ask respondents to indicate the degree to which their health limits moderate 
activities (moving a table, playing golf) and more strenuous activity (climbing several flights 
of stairs). Scores range from 0 to 100, with higher scores indicating greater physical 
functioning. This scale has demonstrated adequate reliability and validity[30] and is widely 
used in studies of cancer patients [13, 31].
Upper body muscle strength was assessed at each assessment with the JAMAR 5030J1 Hand 
Dynamometer [21] in participants who reported no surgery in their hands or wrists in the 
previous 3 months and no history of arthritis. Dominant hand grip strength force measured 
in pounds was assessed twice at each visit; the mean score was used in statistical analyses. 
This instrument has demonstrated adequate reliability and validity in adults [22].
Lower body muscle strength was assessed at each assessment using the Chair Rise Test [16]. 
Participants were asked to rise as many times as possible within 30 seconds without using 
their arms. The number of rises was recorded. This test has demonstrated adequate reliability 
and validity in older adults [16] and is widely used in studies of cancer patients [3, 28].
Weekly exercise activity was assessed at baseline using the Godin Leisure-Time Exercise 
Questionnaire [10], which asks respondents to indicate the frequency with which they 
engaged in mild, moderate, or strenuous exercise in the previous week. Per standard scoring, 
a total weekly activity score was calculated [10]. This measure has demonstrated adequate 
reliability and validity in adults [11] and is widely used in studies of cancer patients [6].
Statistical Analysis
Analyses were limited to patients who completed the baseline assessment and at least one 
follow-up assessment for at least one physical functioning measure. Sixty-two ADT 
recipients and 86 controls were included based on this criterion. Chi-square and t-tests were 
conducted to examine differences between groups on demographic and clinical factors. Age 
was included as a covariate in all mixed models due to its strong association with physical 
functioning and muscle strength. Other demographic and clinical factors that demonstrated 
marginally-significant differences (p < .10) between groups were included as additional 
covariates.
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Mixed model analyses were used to examine differences in change over time in physical 
functioning measures between groups. These analyses were conducted using PROC MIXED 
in SAS, Version 9.3 (Cary, NC). Unlike repeated-measures analysis of variance, mixed 
model analyses allow for the use of all available data at each time point without imputing 
missing data [25]. In order to control Type I error, omnibus analyses were conducted for 
each outcome to examine the group by time interaction for the ADT recipients compared to 
controls. For significant interactions, additional mixed models examined between-group 
differences at each assessment, and unadjusted mixed models examined within-group 
change over time. A two-sided alpha value of .05 was used as the criterion for statistical 
significance. Cohen’s d [5] was used to calculate effect sizes for group differences, and 0.5 
standard deviations was used as a cutoff for clinically-significant differences between 
groups [20]. Unadjusted mixed models were used to produce estimated means of outcome 
variables for both groups. Exploratory linear regression analyses were conducted to identify 
baseline predictors of decline in physical functioning in ADT recipients. In these analyses, 
12-month outcome measures were regressed on baseline scores as well as potential 
predictors.
Results
Demographic & Medical Characteristics
Among ADT recipients, 56 completed the baseline assessment on or before the day of their 
first ADT injection; 6 were assessed from 1 to 5 days after their first ADT injection. 
Twenty-five (40%) ADT recipients underwent radiation concurrently with ADT treatment. 
Demographic and clinical characteristics are shown in Table 1. ADT recipients reported 
more medical comorbidities, had higher Gleason scores, and were more likely to have 
metastatic disease than controls (ps ≤.004). In addition, ADT recipients had fewer years of 
education and were less likely to be White than controls (ps ≤.07). Thus, medical 
comorbidities, education, race, Gleason score, and prostate cancer infiltration were included 
as covariates in subsequent analyses. Because ADT is often prescribed for patients with 
higher Gleason score or metastatic disease (i.e., more advanced disease), separate analyses 
were also conducted without these covariates.
Changes in Physical Functioning
Figure 1 presents adjusted group means for self-reported physical functioning. There was a 
significant group by time interaction with and without controlling for Gleason score (ps<.
001). Physical functioning worsened over time in ADT recipients (p < .001) but did not 
change over time in controls (p=.42). In both sets of analyses, there were no group 
differences at baseline (ps≥.31); however, ADT recipients reported worse physical 
functioning than controls at 6 months (ps≤.05, d=0.71), and 12 months (ps≤.002, d=0.92).
Figure 2 presents adjusted group means for grip strength. A significant group by time 
interaction was not observed when controlling for Gleason score or metastatic disease (p=.
20). However, secondary analyses not controlling for disease severity found a significant 
group by time interaction (p=.01), such that grip strength worsened over time in ADT 
recipients (p=.04) but did not change in controls (p=.18). No group differences in grip 
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strength were evident at baseline (p=.34) or 6 months (p=.06), but ADT recipients 
demonstrated significantly worse grip strength than controls at 12 months (p=.01, d=0.46).
Figure 3 presents adjusted group means for chair rise performance. There were significant 
group by time interactions when controlling for disease severity (p=.05) and when not 
controlling for disease severity (p=.02). Chair rise scores did not change over time in ADT 
recipients (p=.81) but improved over time in controls (p<.001). When controlling for disease 
severity there were no group differences at any assessment (ps≥.16). Secondary analyses 
that did not control for disease severity found no group differences at baseline (p=.14), but 
ADT recipients demonstrated significantly worse chair rise scores than controls at 6 months 
(p=.02; d=.93) and 12 months (p=.003, d=1.05).
Predictors of Changes in Physical Functioning
Analyses were conducted to examine predictors of decline in grip strength, chair rise, and 
physical functioning in ADT recipients. Greater declines in physical functioning were 
associated with higher Gleason scores at baseline, more medical comorbidities, and less 
exercise at baseline (ps≤.05); declines in physical functioning were not associated with 
disease infiltration, age, BMI, and concurrent radiotherapy (ps≥.15). Changes in grip 
strength and chair rise were not related to Gleason scores, disease infiltration, age, BMI, 
medical comorbidities, concurrent radiotherapy, and exercise (ps≥.06).
Discussion
This study examined changes in self-reported physical functioning and upper and lower 
body muscle strength over 12 months in men with prostate cancer receiving ADT and men 
with prostate cancer treated with prostatectomy only. Findings largely confirmed hypotheses 
that treatment with ADT would be associated with self-reported physical functioning and 
loss of muscle strength.
Self-reported physical functioning declined in ADT recipients but remained stable in the 
control group, with differences between groups evident at six months and 12 months. The 
direction and timing of changes in physical functioning are consistent with previous research 
[1, 14]. Differences between groups at 12 months reflected a large effect size and exceeded 
the cut-off [20] for clinically-significant change. Primary analyses controlling for disease 
severity found no group differences for change in upper body muscle strength; however, 
secondary analyses not controlling for disease severity did find a significant effect. Upper 
body muscle strength declined in ADT recipients but remained stable in controls. This is 
partially consistent with previous research. Alibhai and colleagues found that ADT 
recipients’ upper body strength scores decreased at 3 months and remained stable thereafter 
[1]. Although the magnitude of change was consistent in both studies, we found that ADT 
recipients demonstrated progressively worsening upper body strength over the 12 month 
follow-up period. We also found that ADT recipients demonstrated worse upper body 
strength than controls 12 months, reflecting a small to medium effect size that do not meet 
the cut-off [20] for clinically-significant differences. These findings suggest that ADT may 
have a gradual negative impact on upper body strength over the course of a year of 
treatment. This pattern of findings suggests that ADT is associated with clinically-
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meaningful declines in physical functioning which occur within six months after starting 
ADT and persist or worsen over time.
Lower body strength unexpectedly remained stable over time in ADT recipients but 
improved significantly in controls. The reason for the improvement in the control group is 
unclear. One possibility is that improvement may reflect practice effects, whereby positive 
changes in performance are due to familiarity with the task [19]. Improvements in controls’ 
chair rise scores may also reflect improved functioning over time after prostatectomy. 
Regardless of the reason, analyses that did not control for disease severity found that ADT 
recipients performed worse than controls at 6 months and continued to perform worse at 12 
months. The difference at 12 months reflects a large effect size that exceeded the cut-off 
[20] for a clinically-significant difference. These findings are in contrast to previous 
longitudinal research which failed to find any differences in lower body functioning between 
ADT-treated patients and controls [1]; however, cross-sectional analyses have consistently 
demonstrated that ADT recipients perform worse on measures of lower body strength than 
controls [7, 18].
Exploratory analyses found that, among ADT recipients, those with higher Gleason scores, 
less exercise, and more medical comorbidities before starting ADT reported steeper declines 
in physical functioning over time. The exercise-related finding is in line with previous 
research in ADT recipients demonstrating the benefits of exercise for protecting against 
muscle loss [8]. Moreover, exercise in ADT recipients has demonstrated improvements in 
blood pressure, depression, and fatigue [6]. Together, these findings may aid clinicians in 
discussions regarding expected side-effects of ADT use in men with prostate cancer.
This study’s strengths include the use of a longitudinal design and the recruitment of 
prostate cancer control group. This study also has several limitations. First, because 
participants were followed for only 12 months, we are unable to determine whether the 
declines in physical functioning persist or worsen with continued administration beyond one 
year. Also, this study did not examine men who were scheduled to discontinue ADT (i.e., an 
intermittent therapy group), which would have permitted examinations of whether the 
declines in physical functioning are reversible. In addition, biological measures were not 
used to examine correspondence between loss of muscle mass and loss of muscle strength as 
well as physical functioning. The possibility that non-significant results were due to 
insufficient power cannot be ruled out. Osteoarthritis and musculoskeletal pain are potential 
confounders that were not assessed. Future studies should include extended follow-up for 
men receiving continuous ADT to determine its long-term impact and examine the 
possibility that declines may be reversible with discontinuation of ADT. There is also a need 
to examine a more comprehensive set of predictors of decline in physical functioning, 
including body composition and frailty. Because of the observational rather than 
experimental nature of this study, other factors that differed between groups besides ADT 
administration (e.g., disease severity) cannot be ruled out as contributors to group 
differences in physical functioning. Accordingly, the secondary analyses we conducted that 
did not control for disease severity must be interpreted with caution.
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In conclusion, ADT was found to be associated with declines in self-reported physical 
functioning, upper-body muscle strength, and lower body muscle strength. These findings 
have important clinical implications and should be considered in discussions of the risks and 
benefits of ADT.
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Figure 1. 
Estimated means of physical functioning scores by group.
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Figure 2. 
Estimated means of grip strength scores by group.
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Figure 3. 
Estimated means of chair rise scores by group.
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Table 1
Demographic and Clinical Characteristics of the Sample
Characteristic ADT Recipients (n = 62) Controls (n = 86) p
Age, years .79
 Mean 68.12 67.76
 SD 8.71 7.35
Time since diagnosis, years .37
 Mean 3.78 4.50
 SD 4.95 4.47
Body mass index, kg/m2 .16
 Mean 28.32 29.41
 SD 4.23 4.17
Comorbidity index score .004
 Mean 2.84 2.40
 SD 1.04 0.84
  Characteristic No. (%) No. (%) p
Education .07
 ≤12 years 23 (37) 18 (21)
 13 – 16 years 32 (52) 51 (59)
 ≥17 years 7 (11) 17 (20)
Race .03
 White 53 (85) 83 (97)
 Nonwhite 9 (15) 3 (4)
Ethnicity .64
 Hispanic 1 (1) 3 (3)
 Non-Hispanic 60 (98) 82 (96)
 Missing 1 (1) 1 (1)
Gleason score < .001
 4–6 8 (13) 41 (48)
 7 16 (26) 39 (45)
 8 14 (23) 2 (2)
 9–10 7 (11) 0 (0.0)
 Missing 17 (27) 4 (5)
Prostate Cancer Infiltration .01
 Regional 43 (69) 85 (99)
 Metastatic 4 (6) 0 (0)
 Missing 15 (24) 1 (1)
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Note. N = 236. SD = standard deviation. p values calculated using Fisher’s exact test for categorical variables and t-tests for continuous variables. 
Missing levels were excluded from calculation of p values.
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